经导管与外科主动脉瓣置换术治疗重度主动脉瓣狭窄:Meta分析与试验序贯分析
该系统评价纳入8项随机对照试验(高危5274例、低危3661例),比较经导管主动脉瓣植入与外科主动脉瓣置换。常规Meta分析显示低危组经导管治疗1年死亡及死亡或致残性卒中风险较低,但试验序贯分析提示证据可能虚假,需更多数据才能得出确定性结论。
要点
- 高危组经导管治疗1年死亡风险无显著降低(RR 0.93,95%CI 0.81-1.08,P=.345)。
- 低危组常规Meta分析1年死亡RR 0.67(95%CI 0.47-0.96),但试验序贯分析P=.116,提示证据可能虚假。
- 低危组死亡或致残性卒中常规Meta分析RR 0.68(95%CI 0.50-0.93),试验序贯分析P=.053,需更多数据。
核心结论
- 常规Meta分析方法可能过早地宣布经导管主动脉瓣植入相较于外科主动脉瓣置换术在早期减少了不良结局。
研究设计与样本
- 检索随机对照试验的数据库,按实用性风险分类分为较高危和较低危随机对照试验,共纳入8项随机对照试验(高危5274例,低危3661例)。
主要发现
- 高危试验显示经导管主动脉瓣植入1年死亡无显著降低(RR 0.93,95%CI 0.81-1.08,P=.345)。
- 低危试验常规Meta分析提示死亡风险较低(RR 0.67,95%CI 0.47-0.96,P=.031),但试验序贯分析提示证据可能虚假(P=.116),需更多数据(所需信息量=5944[59.8%])。
- 高危试验1年死亡或致残性卒中缺乏证据(RR 0.90,95%CI 0.79-1.02,P=.108)。
- 低危试验常规Meta分析提示经导管主动脉瓣植入死亡或致残性卒中风险较低(RR 0.68,95%CI 0.50-0.93,P=.014),但试验序贯分析提示证据可能虚假(P=.053),需更多数据(所需信息量=5122[69.4%])。
- 随访结果对两个主要结局在各风险类别中均提供不确定证据。
关键数值与推荐
- 主要结局为1年及最长随访时的死亡和死亡或致残性卒中的复合终点。
- 计算所需信息量时考虑5%的I类错误和90%的把握度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 低危试验中试验序贯分析提示证据可能虚假(P=.116),需更多数据才能得出确定性获益(所需信息量=5944[59.8%])。
- 低危试验死亡或致残性卒中试验序贯分析提示证据可能虚假(P=.053),需更多数据才能得出确定性获益(所需信息量=5122[69.4%])。
- 随访结果对两个主要结局在各风险类别中均提供不确定证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Randomized controlled trials comparing transcatheter aortic valve implantation with surgical aortic valve replacement demonstrate conflicting evidence, particularly in low-risk patients. We aim to reevaluate the evidence using trial sequential analysis, balancing type I and II errors, and compare with conventional meta-analysis. METHODS: Databases were searched for randomized controlled trials, which were divided into higher-risk and lower-risk randomized controlled trials according to a pragmatic risk classification. Primary outcomes were death and a composite end point of death or disabling stroke assessed at 1 year and maximum follow-up. Conventional meta-analysis and trial sequential analysis were performed, and the required information size was calculated considering a type I error of 5% and a power of 90%. RESULTS: Eight randomized controlled trials (n = 5274 higher-risk and 3661 lower-risk patients) were included. Higher-risk trials showed no significant reduction in death at 1 year with transcatheter aortic valve implantation (relative risk, 0.93, 95% CI, 0.81-1.08, P = .345). Lower-risk trials suggested lower death risk on conventional meta-analysis (relative risk, 0.67, 95% CI, 0.47-0.96, P = .031), but trial sequential analysis indicated potential spurious evidence (P = .116), necessitating more data for conclusive benefit (required information size = 5944 [59.8%]). For death or disabling stroke at 1 year, higher-risk trials lacked evidence (relative risk, 0.90, 95% CI, 0.79-1.02, P = .108). In lower-risk trials, transcatheter aortic valve implantation indicated lower risk in conventional meta-analysis (relative risk, 0.68, 95% CI, 0.50-0.93, P = .014), but trial sequential analysis suggested potential spurious evidence (P = .053), necessitating more data for conclusive benefit (required information size = 5122 [69.4%]). Follow-up results provided inconclusive evidence for both primary outcomes across risk categories. CONCLUSIONS: Conventional meta-analysis methods may have prematurely declared an early reduction of negative outcomes after transcatheter aortic valve implantation when compared with surgical aortic valve replacement.
引用
- Jacquemyn X, Sá MP, Rega F, et al. Transcatheter versus surgical aortic valve replacement for severe aortic valve stenosis: Meta-analysis with trial sequential analysis. J Thorac Cardiovasc Surg. 2024. PMID: 38688452. doi:10.1016/j.jtcvs.2024.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。